We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
-
Our programs are designed to provide relevant information to support people with bleeding disorders and their families with their ability to make informed choices.
Take a look. -
Fundraisers and events help us raise awareness and generate crucial resources in support of the bleeding disorders community. Join us at our next event and see how you can get involved. Find something to do.
-
Our grassroots network is an integral part of our larger community. Team up with us and see what a huge difference a little bit of your time can make.
Take action.
News & Events
The designation is for people with hemophilia A without inhibitors.
Genentech has announced that the U.S. Food and Drug Administration (FDA) has granted “breakthrough” therapy designation to HEMLIBRA® for people with hemophilia A, without inhibitors. Breakthrough drugs are put on a fast-track approval program and given intensive guidance from the FDA. The therapy was co-developed by Genentech, Chugai and Roche.
NHF is expanding its work with the bleeding disorders community around the world.
ICER is an independent and non-partisan research organization that evaluates the clinical and economic value of prescription drugs, medical tests, and other healthcare and healthcare delivery innovations.
Grifols, S.A. recently announced that in 2017, the company donated over 25 million international units (IU) of factor products used to treat hemophilia A and B. According to a recent press release, the donation is part of Grifols’ commitment to provide a minimum of 200 million IU of factor to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over a span of eight years – Grifols began this commitment in 2014. The company expects to make an additional donation of nearly 25 million IUs in 2018.
View Archives
